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Introduction. The Portuguese healthcare system had to adapt at short notice to the COVID-19 pandemic. We implemented
workflow changes to our molecular pathology laboratory, a national reference center, to maximize safety and productivity. We
assess the impact this situation had on our caseload and what conclusions can be drawn about the wider impact of the
pandemic in oncological therapy in Portugal. Material and Methods. We reviewed our database for all oncological molecular
tests requested between March and April of 2019 and 2020. For each case, we recorded age, sex, region of the country,
requesting institution, sample type, testing method, and turnaround time (TAT). A comparison between years was made.
Results. The total number of tests decreased from 421 in 2019 to 319 in 2020 (p = 0:0027). The greatest reduction was in clinical
trial-related cases. Routine cases were similar between years (267 vs. 256). TAT was higher in 2019 (mean 15 days vs. 12.3 days;
p = 0:0003). Medium- to large-sized public hospitals in the north of the country were mostly responsible for the reduction in
cases (p = 0:0153). Conclusions. Case reduction was observed at hospitals that have mostly been involved in the treatment of
COVID-19 and in the north of the country, the region worst-hit by the pandemic. Similar to other studies, our TAT decreased,
even with a similar number of routine cases. Thus, we conclude that it is possible to successfully adapt the workflow of a
molecular pathology laboratory to new safety standards without losing efficiency.
1. Introduction
On the second of March 2020, Portugal confirmed its first
case of coronavirus disease 2019 (COVID-19) [1]. The num-
ber of infected rose rapidly, and by the end of April, there
were more than 25,000 COVID-19 patients with nearly
1,000 people dead from the disease [2]. Although tragic, this
scenario is far less severe than what was seen in other
European countries, namely, Italy and Spain [3].
This might be explained in part by the swift measures
taken by the Portuguese government, which implemented a
state of emergency on the 18th of March, merely a fortnight
since the first confirmed cases and with a single confirmed
death in the country. These measures included, amongst
others, closing of schools and daycare, mandatory remote
work, closing of all nonessential commerce and services,
and confinement of most of the population to their resi-
dences, with a few exceptions [4].
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It is of note that the impact of the disease in Portugal was
heterogeneous, being felt with more intensity in the north of
the country and, to a lesser degree, in Lisbon and surround-
ing areas [2].
Nationally, the government issued guidelines for a
reorganization of the Portuguese National Health Service
(PNHS) on the 16th of March. As a result, all elective proce-
dures and surgeries were suspended as resources were allo-
cated to the treatment of COVID-19 patients. Oncological
therapy was deemed the exception, however, and guidelines
were emitted to enable continued therapy when safe condi-
tions could be fulfilled and with reduced staff levels and other
constraints related to the contingency programs [5, 6].
Our molecular laboratory (IPATIMUP, Porto) is a
ISO15189-accredited laboratory and one of the national ref-
erence centers for molecular pathology in Portugal, handling
samples from all over the country, from both public and
private institutions [7–12].
During the COVID-19 outbreak, our laboratory kept per-
forming predictive molecular testing on tissue (cytological
and histological) and liquid biopsy samples. However, to bet-
ter preserve the health and safety of our workers, in keeping
with the 1-meter distance rule [13] and in an effort to mini-
mize physical interactions between staff, some changes had
to be made to our workflow: hands-on laboratory and clerk
workers were divided in two teams of equal size, each rotat-
ing through the laboratory every 15 days; all staff allocated
to the interpretation of molecular tests were placed in a
regimen of remote working from home.
Given these constraints, we wondered what impact the
current pandemic had in our case load of molecular tests
and what conclusions could be drawn from this data about
the impact of the COVID-19 pandemic on oncological ther-
apy in Portugal. We also compared our results with a similar
laboratory localized in Italy [13], a country most severely
affected by the pandemic.
2. Materials and Methods
To monitor the impact of COVID-19 in the predictive onco-
logic molecular tests performed at our molecular laboratory,
we reviewed our case database for all molecular tests
requested between the period of March 16th and April 15th
of 2019 and 2020, creating two separate cohorts. Only onco-
logical somatic genomic tests were included in our analysis.
Germinative genomic tests as well as tests for nonneoplastic
diseases were excluded. Cases evaluated in the context of
clinical trials, for which patient data was not available, were
removed form age analysis but included in all others. Cases
not signed out as of the time of writing were excluded from
turnaround time (TAT) analysis but included in all others.
The following variables were recorded for each case: age
and sex, the region of the country from where the patient
samples were received, whether the requesting institution
was public or private, sample type, adopted testing method-
ologies, and turnaround time (TAT). In particular, TAT
was considered the time between the receipts of samples to
clinical reporting.
To analyze the provenance of the patients, we followed
the Pathology National Hospital Reference Network guide-
lines, dividing the country into the following regions: north,
center, Lisbon and Tejo Valley (LTV), and Algarve. Accord-
ing to the same document, national health service institu-
tions were classified as either type I (containing basic and
peripheral pathology laboratories), type II (containing inter-
mediate level pathology laboratories), and type III (contain-
ing highly specialized pathology laboratories, located in
central hospitals, academic, and oncological institutions)
[14]. Private laboratories were grouped together under one
category (PL).
Sample types were classified as either liquid biopsies (LB) or
tissue/cytology material (TC), and the latter submitted either in
paraffin blocks or glass slides. The following testing methodolo-
gies were used: next-generation sequencing (NGS), polymerase
chain reaction- (PCR-) based capillary electrophoresis, Sanger
sequencing, the IdyllaTM (Biocartis, Mechelen, Belgium) plat-
form (fully automated real-time PCR), and digital PCR. NGS
methodology in our laboratory mainly serves patients with lung
cancer, some cases of CNS neoplasms, and cases of occult pri-
mary tumors, in search of actionable therapeutic targets. We
use the oncomine FOCUS assay panel (Thermo Fisher Scien-
tifics, Waltham, Massachusetts, USA). This panel includes 52
genes tested for a number of genomic alterations. Briefly, 35
genes are analyzed for hotspot mutations/insertion/deletion
(in detail: EGFR, BRAF, KRAS, NRAS, HER2, HER4, MET,
PIK3CA, and ALK); copy number variations (CNV) are evalu-
ated for 19 genes, while gene fusion detection is covered for 23
genes, includingALK,ROS1,KIF5B-RET,NTRK, among others.
This panel is run on Ion S5™ or S5 XL™ (Ion Torrent, Thermo
Fisher, USA) with a minimum coverage of 500x and 2000x for
DNA and RNA, respectively. Sanger sequencing in our labora-
tory is used in GIST tumors for PDGFRA and C-KIT genes, in
some cases for BRAF in colon carcinomas and melanomas
and PIK3CA in advanced breast carcinoma. In patients with
clinical requests for the determination of microsatellite instabil-
ity, a PCR (pentaplex) is performed and, after confirming that
the amplification has occurred as expected, the PCR product
run through clot analysis on the ABI3500 (Thermo Fisher,
USA). The five monomorphic markers (BAT-26, BAT-25,
NR-24, NR-21, and NR-27) are analyzed according to their
standards. The fully automated real-time PCR (RT-PCR) plat-
form IdyllaTM (Biocartis, Mechelen, Belgium) is used essentially
for colon/rectal tumors in order to determine the status of RAS
in routine cases as in clinical trials where our laboratory is the
reference center. To obtain comprehensive information on clin-
ically relevant mutational hotspots, two cartridges are sequen-
tially employed in the following algorithm: KRAS cartridge
first, moving on to NRAS/BRAF if KRAS mutations are not
detected. When assays need to be highly sensitive, for example
to detect T790M resistance mutation, Digital PCR by TaqMan
probes on the 3D Digital system QuantStudio PCR System
(Thermo Fisher Scientifics) is carried out. Preliminary to all
abovementioned assays is the staff pathologist assurance that
DNA/RNA is really extracted from viable tissue areas in which
the tumor ratio is optimal, and the percentage of inflammatory
cells and potentially amplification inhibitors (such asmucin and
melanin) is minimal.
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2.1. Statistical Analysis. A comparative analysis was done
between the two cohorts regarding patient age, sex, sample
size, distribution over time, region of provenance, type of
institution, TAT, sample type, and exam type. Continuous
variables were compared using the Mann-Whitney unpaired
t-test, and discrete variables were compared using the Fisher
or chi-squared tests, as appropriate. Statistical analysis was
performed using the GraphPad Prism version 6.01 for
Windows (GraphPad Software, La Jolla, California, USA,
http://www.graphpad.com).
3. Results
3.1. Laboratory Workflow. The staff of the Molecular Labora-
tory of IPATIMUP is composed of 14 people with different
skills, working full time at the laboratory (35 hours per week).
From this total, five are fully dedicated to somatic genomic
testing, including four biomedical assistants and one pathol-
ogist. During the COVID-19 outbreak, following the contin-
gency plans of the institute, the director of the laboratory
decided to divide the personnel in two teams shifting
between in loco and remote work every fortnight. Each team
was composed of six people, each including at least of two of
the biomedical scientists dedicated to somatic testing. As
mentioned, a pathologist working remotely supervised the
processing of tissue samples. Interpretation of the results
was done remotely using virtual private network (VPN)
access over the internet to the computers in the laboratory.
All staff were kept working full time, either in loco or
remotely, to guarantee the adequate supply of reagents and
to interpret the molecular testing results under the supervi-
sion of the chief biomedical scientist. Once per week, the
whole team (both member working in loco and from home)
had a virtual meeting to share progress reports and discuss
quality and other relevant issues. All activities related to qual-
ity control were maintained in the same fashion.
3.2. Cohort Description. In 2019, during the period of March
16th to April 15th, a total of 421 molecular tests were per-
formed in our laboratory. From these, 80 were from nonon-
cological samples and were excluded from analysis. This left
us with 341 molecular tests performed on oncological cases.
Of these, 74 were performed under clinical trial protocols
and had no complete patient information. This left us with
a total of 267 molecular tests with full data available for
analysis.
In comparison, in the same period of 2020, a total of 319
molecular tests were performed in our laboratory, which is
102 less than the previous year (p = 0:0027). Interestingly,
only 35 were from nononcological samples. The total of
molecular tests carried out on oncological cases was 284.
Similarly, to the number of nononcological samples, there
was also a significant reduction in tests performed in the con-
text of our clinical trial protocols, totaling only 28 in 2020.
Since a further 10 cases were not signed out as of the time
of writing, we were left with a total of 246 molecular tests
with full data available for analysis in 2020.
A summary description of our cohorts can be found in
Figure 1.
3.3. Demographics and Turnaround Time. In terms of demo-
graphics, from the 267 molecular tests with data available for
demographic analysis performed in 2019, 103 (30.2%)
belonged to female patients and 164 (48.1%) to male patients.
The median age was 67 years (mean, 65.4 years; range, 0-89).
From the 256 molecular tests with data available for demo-
graphic analysis performed in 2020, 101 (39.5%) belonged
to female patients and 155 (60.5%) to male patients. The
median age was 66 years (mean, 65.3 years; range, 36-94).
The case distribution by age can be better appreciated in
Figure 2. No statistically significant differences were found
between the two cohorts with regard to age (p = 0:2070).
We calculated the TAT for each cohort. In 2019, the
median TAT was of 15 days (mean, 14.8 days; range, 1-46),
and in 2020, the median TAT was of 12 days (mean, 12.3
days; range, 2-42). A statistically significant difference was
found between the two cohorts in terms of TAT (p = 0:0003).
The TAT distribution can be seen in Figure 2.
3.4. Requesting Institutions and Geographical Differences.
Special care was taken to assess the features of the institutions
issuing fewer requests. Our data show that the overall
decrease in testing is mostly due to the PNHS institutions
(301 requests in 2019 vs. 236 requests in 2020). Interestingly
though, whereas PNHS type I institutions (i.e., smaller
regional hospitals) show an increase in both number and rel-
ative percentage of molecular tests requested [99 (29.03%) vs.
102 (35.92%)], PNS types II and III (i.e., medium to large
hospitals and reference centers) featured a significant
decrease in the number of tests requested [202 (59.2%) vs.
134 (47.2%)]. In fact, since the number of tests requested by
private laboratories increased, the reduction in the number
of requested tests comes solely from types II and III PNS
institutions (p = 0:0153).
In terms of region, the largest decrease in testing comes
from the Northern region of Portugal, encompassing all ter-
ritory roughly from the Spanish border with Galiza down to
the Douro river [165 (48.4%) vs. 129 (45.42%)]. The cases
from LTV and Algarve also decreased, whereas the cases
from the Center saw a slight increase (p = 0:0146).
These results can be seen in greater detail in Table 1.
3.5. Tissue and Cytology vs. Liquid Biopsies. Liquid biopsies
are mostly done in our institution for the detection of EGFR
T790M resistance mutations in the context of lung cancer. It
is worth noting that although the absolute number of both
sample types decreased, this was more evident in liquid biop-
sies. This difference in the distribution showed statistical sig-
nificance (p = 0:0067).
3.6. Molecular Tests Performed. Comparing 2019 with 2020,
we found a significant decrease in the number and propor-
tion of IdyllaTM tests [145 (42.5%) vs. 80 (28.2%)], as well
as an increase in the number of molecular tests performed
by Sanger sequencing [29 (8.5%) vs. 38 (13.38%)] and PCR-
based capillary electrophoresis [2 (0.6%) vs. 17 (6.0%)].
These differences are statistically significant (p < 0:0001).
The remaining test types (digital PCR and NGS) were per-
formed at similar levels between both years, with NGS
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showing a slight decrease in absolute numbers but a slight
increase in preponderance. These results can better be appre-
ciated in Table 1 and are schematized on Figure 3.
It is of note that the tests performed in the context of
clinical trials are all done in the IdyllaTM platform check
material and methods, and those decreased by a total of 46,
year-on-year.
4. Discussion
The comparison between our two cohorts highlights the
challenges that the Portuguese National Health System
(PNHS) underwent during the first peak of the COVID-19
pandemic. In our series, there was a decrease in the absolute
number of molecular tests. However, if we exclude those
performed under clinical trial protocols, we can see that the
difference between 2019 and 2020 is not that expressive
(267 vs. 256 routine cases tested, respectively). In fact, both
series seemed to be equivalent, at least in terms of age and
sex distribution. Thus, it is not farfetched to conclude that
no significant changes were observed in the volume of rou-
tine predictive molecular testing in our institution.
These results are similar to what was recently reported in
an Italian reference center [13], where even during the
COVID-19 outbreak, oncological patients were properly
tested for targeted treatment, as usual. Conversely, while
molecular testing is maintained, the traditional histopathology
and cytopathology has during the same time period decreased
in our (data not shown) and in other institutions [15].
Remarkably, our molecular laboratory adapted to the
health emergency and implemented measures to limit virus
transmission, focusing on maintaining adequate social
⁎Clinical trial protocol tests lack age data, but were included in other analysis;
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as of time of writing⁎
267 molecular tests
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analysis
Figure 1: Cohort description.
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distance between staffmembers [16, 17]. For this reason and
to avoid unnecessary contamination or exposure of our tech-
nicians, we reduced our team by half and had teams rotate
each 15 days. Despite the reduction in staff (approx. 50%),
our TAT was significantly better in 2020, during the peak
of the pandemic, compared with the same period of last year.
This is particularly remarkable if we consider that the total
reduction in case load was of only around 5%, which high-
lights the successful adaption of our molecular pathology lab-
oratory to the new work rotation: similar numbers of routine
cases were handled between the two periods, and the
response times were actually faster. As the pandemic pro-
gresses and we become accustomed to this new workflow
organization, it is conceivable that some, if not most, of these
changes may be kept after the pandemic, resulting in similar
or better patient care, a less crowded work environment, and
better satisfaction with work life for our technicians.
In a similar study, Malapelle et al. [13] also showed a sig-
nificant reduction of the TAT in the pandemic period. In that
study, the main reason pointed out by the authors was the
adoption and prioritization of a fully automated testing plat-
form, which proved a valuable tool in ensuring accurate bio-
marker evaluation and sustainable laboratory activity.
In fact, the published literature regarding the adoption of
the IdyllaTM platform [18–20] shows that the technical
switch toward such a system allows for a reduction in work-
ing hours, which is a clear benefit during situations of greater
constraints, like the COVID-19 pandemic. Because these
techniques require less hands-on time, they allow for more
social distancing and better safety risk management. There
are some disadvantages in the adoption of fully automated
systems, however: increased cost per patient in some types
of cancer, as lung cancer does not detect all actionable muta-
tions recommended; the need for validation with NGS in
some cases; and a relative inflexibility of the platform—this
approach cannot be adopted in situations where there is a
need to analyze a large panel of genes, as in the case of lung
cancer patients. [10]
Contrary to what has been reported by Malapelle et al.
[13], we observed a decrease of the use of the IdyllaTM
platform.
It is conceivable that IdyllaTM is clearly advantageous
during the pandemic [13, 18–20], being fast and easy with
minimal analysis or hands-on time. However, in our labora-
tory, many of the tests usually performed using this platform
are carried out in the context of clinical trials, and these
decreased significantly in number. Despite the reduced num-
bers of staff, we did not observe an increase in the use of Idyl-
laTM for routine cases. This may be explained by the fact that
in our institution most of the cases analyzed are from lung
cancer patients, followed by colon cancer and SNC tumors,
making it nearly impossible to switch our routine from NGS.
Since molecular testing is based on formalin-fixed and
paraffin-embedded (FFPE) tissue and fixed smears, the possi-
bility that the SARS-CoV-2 virus was present in samples was
minimal [21]. Conversely, liquid-based cytology may repre-
sent a potential source of transmission if fixatives with low
alcohol concentrations (<70%) are used. Since we cannot
control the fixation process upstream, we did not use this
type of material for molecular analysis during the pandemic.
Serum for liquid biopsy analysis is submitted fresh and may
represent a potential source of transmission; thus, we signif-
icantly reduced this type of assay.
Moving to the perspective our data gives us for the coun-
try as a whole, we noticed changes in the numbers coming
from different types of requesting institutions. On the one
hand, we did not see a reduction in cases from private
laboratories and in fact even observed a slight increase. This
may be explained by the fact that the private health sector
was only marginally involved in the treatment of COVID-19
patients in our country. In contrast, we did see a significant
reduction in the number of cases from public hospitals. This
is more evident in the most-specialized institutions (PNHS
types II and III). During the pandemic, many of these became
reference centers for COVID-19 patients who, in general, were
not treated in community hospitals (which tendentially are
classified as PNHS type I). In terms of region, it is interesting
to note that the largest and most significant decrease in tests
ordered comes from the north of the country where our labo-
ratory is located (Porto). The north region was by far the
worst-hit region in Portugal, with approximately 2.5× the
number of cases of the second worst-hit region, LVT (14726
total cases in the north vs. 5815 total cases in LVT, as of April
30th) [2]. This raises the possibility that the impact of the
pandemic on oncological management could have been
worse if the number of cases had been significantly higher
in the country.
In conclusion, our findings show that during the
























Figure 2: Distribution of patient age and turnaround time.
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to successfully adapt and maintain oncological therapy
within reasonable levels, while locking down the country
and changing hospital routine to face the new infectious dis-
ease. Our results also reinforce the findings of other studies
[13, 15] that COVID-19 emergency is changing the way we
practice not only histo- and cytopathology but also predictive
molecular pathology. This activity is crucial to extend and
improve the life expectancy and quality of our oncological
patients, and it is possible to successfully adapt the workflow
of a molecular pathology laboratory to new safety standards
without losing efficiency during these exceptional times,
using different strategies adapted to the reality at hand.
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Table 1: Comparison between discrete variables evaluated in both cohorts.
Evaluated variables Type 2019 (N) 2019 (%) 2020 (N) 2020 (%) p value
Institution
PNHS type I 99 29.03% 102 35.92%
0.0153
PNHS type II 111 32.55% 66 23.24%
PNHS type III 91 26.69% 68 23.94%
PL 40 11.73% 48 16.90%
Region
North 165 48.39% 129 45.42%
0.0146
Center 39 11.44% 45 15.85%
LTV 122 35.78% 108 38.03%
Algarve 15 4.40% 2 0.70%
Sample
LB 36 10.56% 13 4.58%
0.0067
TCB 305 89.44% 271 95.42%
Molecular test
NGS 164 48.09% 147 51.76%
<0.0001
Sanger 29 8.50% 38 13.38%
Idylla 145 42.52% 80 28.17%
PCR-based capillary electrophoresis 2 0.59% 17 5.99%
























Figure 3: Percentage of molecular tests performed in 2019 vs. 2020.
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